Under this "old" model of intellectual property (IP), biotech firms raced to file a "fortress" of patents around newly discovered genes, closing off avenues of research for their competitors.
Some copyright owners in Europe and the US are using IP addresses gathered by monitoring firms to apply for court orders obliging internet service providers to hand over the physical addresses associated with them.